Linda Kozick


Linda M. Kozick has more than 25 years of experience in the biopharmaceutical industry, including 15 years of strategic commercial leadership in oncology with a focus in immuno-oncology. She retired from Bristol-Myers Squibb (BMS) as Vice President and Head of Immuno-Oncology/Oncology Product and Portfolio Strategy and Opdivo and Yervoy Life Cycle Management. Prior to that role, Ms. Kozick was the commercial lead for Opdivo (nivolumab) and was instrumental in helping BMS develop its clinical and commercial strategy for immunology-oncology (I-O), which included combinations with BMS I-O assets and acquisition of external molecules. She currently serves on the boards of directors for Rapt Therapeutics, Inc. and Saugatuck Therapeutics Ltd. Ms. Kozick received her B.S. in Medical Technology and M.S. in Molecular Immunology from SUNY Upstate Medical Center, and her MBA from Chapman University.